Botulinum TOX TYP a 1S
Ended Awarded
- Contract number
- SPE2DR26FBTAF
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,163
Award facts
- Contract value 100% obligated
- $14,162.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $14,162.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Botulinum Toxin Type A 1S. The award, issued on October 31, 2025, with an ultimate completion date of November 13, 2025, carries no set-aside designation, indicating the contractor competed in open procurement. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion enterprise-wide acquisition strategy designed to provide comprehensive pharmaceutical support to Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, with its product portfolio spanning branded and generic pharmaceuticals, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The company's prime vendor contract under PPV-G GEN V, designated SPE2DR with a $499,999,999 ceiling and completion date of December 31, 2036, positions it as a critical pharmaceutical supplier serving DoD healthcare operations globally. This delivery order reflects the company's ongoing role in fulfilling specialized pharmaceutical requirements for military medical facilities, with no subcontractor relationships identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FBTAF?
SPE2DR26FBTAF was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 31, 2025.
How much is contract SPE2DR26FBTAF worth?
The government has obligated $14,163 on SPE2DR26FBTAF.
Is contract SPE2DR26FBTAF an order under another contract?
Yes. SPE2DR26FBTAF is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTAF competed?
The extent of competition for SPE2DR26FBTAF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award